LPA and neoplasm: With regard to the therapeutic aspects of Lp(a), it has been found that the therapeutic efficacy of immune checkpoint inhibitors (ICIs) can be enhanced by strategies that reduce Lp(a) levels (e.g., the use of statins or PCSK9 inhibitors) that enhance the response of tumor-specific cytotoxic T cells.